Is Qiagen’s Stumble An Opportunity For Investors?
Investors are wondering whether to welcome or fear Qiagen’s recent announcement about its CEO’s departure, slowing sales, and business restructuring.
Illumina
ILMN
ILMN
$309.67
-$2.50
-0.8%
BATS BZX Real Time Price as of October 16, 2019, 4:00 p.m. EDT
View Interactive ILMN Charts
Illumina is a developer, manufacturer and marketer of next-generation life-science tools and integrated systems for the analysis of genetic variation and biological function.
News & Analysis: Illumina
The Fool has written over 400 articles on Illumina.
3 Top Healthcare Stocks to Buy Right Now
Success is in these three great healthcare stocks' DNA.
Better Buy: Illumina vs. Guardant Health
Which stock wins in a matchup between a gene sequencing pioneer and a fast-rising liquid biopsy leader?
Merger or Not, Pacific Biosciences Needs to Deliver
The DNA sequencing pioneer promised a $1,000 human genome by early 2019. The price isn't so important, but the technology upgrades will prove critical.
My 3 Top Healthcare Stocks for Long-Term Investors
They're pioneers. They're innovators. And they should continue to be huge winners for investors with long-term perspectives.
5 Top Cancer-Fighting Stocks to Buy Now
Each of these healthcare companies takes a different approach to fighting cancer, but all have what it takes to be long-term winners in your portfolio.
Here's Why Illumina Tumbled 18.7% in July
Growth stagnated in the first half of 2019. Management says it will be temporary.
5 Things Illumina's Management Just Said That You'll Really Want to Know
Are the disappointing results for Illumina a "new normal"? Not at all, according to its top executives.
Illumina Inc (ILMN) Q2 2019 Earnings Call Transcript
ILMN earnings call for the period ending June 30, 2019.
Illumina Hits a Speed Bump in the Second Quarter
The genomic sequencing company reported slower revenue growth because of several issues, including a delay in closing a major population genomics deal.
